OSS, The Netherlands–(BUSINESS WIRE)–Citryll today announced that the first healthy volunteer has been enrolled and dosed in a Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of CIT-013. CIT-013 is a first in class humanized therapeutic antibody targeting Neutrophil Extracellular Trap (NET) formation and clearance. CIT-013 is being developed for autoimmune and chronic inflammatory diseases and other indications where NETs play an important role in pathogenesis.
The first-in-human study is a randomised, double blind, placebo controlled, single ascending dose (SAD) study carried out by the Centre for Human Drug Research (CHDR) in Leiden, The Netherlands, a CRO specialized in early-stage human clinical trials.
Read the full press release here.Back